Guardant Health, Inc. - Common Stock (NQ:GH)

183.69 -1.62 (-0.88%)

Delayed Quote Updated: 9:38 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

This Explosive Biotech Is Taking On a Huge New Market ↗

June 30, 2021

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

Via The Motley Fool

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

June 22, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Insights: Return On Capital Employed ↗

June 21, 2021

During Q1, Guardant Health's (NASDAQ:GH) reported sales totaled $78.67 million. Despite a 18.31% in earnings, the company posted a loss of $107.86 million. Guardant Health...

Via Benzinga

CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

June 18, 2021

From Guardant Health

Via Business Wire

CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

June 18, 2021

From Guardant Health, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip ↗

June 13, 2021

Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: SPFR), the blank-check...

Via Benzinga

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

June 08, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health: Return On Capital Employed Insights ↗

June 04, 2021

In Q1, Guardant Health (NASDAQ:GH) posted sales of $78.67 million. Earnings were up 18.31%, but Guardant Health still reported an overall loss of $107.86 million. Guardant Health...

Via Benzinga

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

June 04, 2021

From Guardant Health, Inc.

Via Business Wire

Cathie Wood Buys $10.5M In Google, Loads Up Another $31.6M In Zoom ↗

June 04, 2021

Cathie Wood-led Ark Investment Management on Thursday bought 4,496 shares, estimated to be worth about $10.55 million, in Google parent Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 ↗

June 03, 2021

Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had...

Via Benzinga

Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer ↗

May 28, 2021

The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras...

Via Benzinga

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

May 28, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists

May 28, 2021

From Guardant Health, Inc.

Via Business Wire

Cathie Wood Loads Up Another $292K In SpaceX Partner Velo3D's SPAC ↗

May 26, 2021

Cathie Wood-led Ark Investment Management on Wednesday bought 29,301 shares, estimated to be worth about $292,131, in the SPAC Jaws Spitfire Acquisition Corp (NYSE: SPFR)...

Via Benzinga

Where Guardant Health Stands With Analysts ↗

May 25, 2021

Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 0 1...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗

May 25, 2021

Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...

Via Benzinga

Cathie Wood Buys Another $42M In Twitter Stock, Also Adds DraftKings, Netflix ↗

May 25, 2021

Cathie Wood-led Ark Investment Management on Monday bought 731,775 shares, estimated to be worth about $41.76 million, in Twitter Inc (NYSE: TWTR) — a day after The Bill and...

Via Benzinga

Cathie Wood Loads Up Yet Another $51M In Coinbase As Shares Slump Amid Bitcoin-Led Crypto Carnage ↗

May 23, 2021

Cathie Wood-led Ark Investment Management on Friday snapped up another 223,181 shares, worth about $50.7 million, in Coinbase Global Inc

Via Benzinga

With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble? ↗

May 22, 2021

Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.

Via The Motley Fool

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 21, 2021

From Guardant Health, Inc.

Via Business Wire

Why Exact Sciences Stock Soared Today ↗

May 20, 2021

The company's Cologuard DNA test appears to be in good shape to maintain its market leadership.

Via The Motley Fool

Guardant Had Colon Cancer Data, But Rival Exact Popped — Here's Why ↗

May 20, 2021

Guardant and Exact are in a "win-win situation," an analyst said Thursday as EXAS stock surged on a comparison to Guardant in colon cancer detection.

Via Investor's Business Daily

Guardant Health to Participate in Upcoming June Investor Conferences

May 20, 2021

From Guardant Health, Inc.

Via Business Wire

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

May 19, 2021

From Guardant Health, Inc.

Via Business Wire

Exact Sciences' First-Quarter Results Show Its Strength Under Pressure ↗

May 15, 2021

Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?

Via The Motley Fool

3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming ↗

May 13, 2021

Falling costs are ushering in a new era of screening for a dreaded disease.

Via The Motley Fool

What 7 Analyst Ratings Have To Say About Guardant Health ↗

May 07, 2021

Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.